Greg Wolf to Cetuximab
This is a "connection" page, showing publications Greg Wolf has written about Cetuximab.
Connection Strength
0.087
-
Banerjee R, Liu M, Bellile E, Schmitd LB, Goto M, Hutchinson MND, Singh P, Zhang S, Damodaran DPV, Nyati MK, Spector ME, Ward B, Wolf G, Casper K, Mierzwa M, D'Silva NJ. Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. Mol Ther. 2022 01 05; 30(1):468-484.
Score: 0.046
-
Swiecicki PL, Li P, Bellile E, Stucken C, Malloy K, Shuman A, Spector ME, Chinn S, Casper K, McLean S, Moyer J, Chepeha D, Wolf GT, Prince M, Bradford C, Nyati M, Eisbruch A, Worden FP, Jolly S, Mierzwa M. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. Head Neck. 2020 08; 42(8):1728-1737.
Score: 0.042